Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.
VEGFR2
combination therapies
hepatocellular carcinoma
immunotherapy
tyrosine kinase inhibitor
Journal
Hepatic oncology
ISSN: 2045-0923
Titre abrégé: Hepat Oncol
Pays: England
ID NLM: 101629607
Informations de publication
Date de publication:
28 May 2020
28 May 2020
Historique:
entrez:
11
7
2020
pubmed:
11
7
2020
medline:
11
7
2020
Statut:
epublish
Résumé
For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of atezolizumab and bevacizumab, a first-line treatment that is superior to the current standard was identified, potentially changing the way we treat HCC. In this review, we summarize current data on systemic treatment of patients with advanced HCC, focusing on combination therapies comprising immune checkpoint inhibitors, TKIs and locoregional therapies. We elucidate findings from recent trials and discuss such challenges as the lack of predictive biomarkers for identification of subgroups that will benefit from novel treatment strategies.
Identifiants
pubmed: 32647565
doi: 10.2217/hep-2020-0004
pmc: PMC7338920
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
HEP20Informations de copyright
© 2020 Christoph Roderburg.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Liver Cancer. 2017 Nov;6(4):253-263
pubmed: 29234629
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Hepatol. 2018 Aug;69(2):353-358
pubmed: 29704513
Z Gastroenterol. 2020 Jun;58(6):542-555
pubmed: 32018315
J Hepatol. 2019 Apr;70(4):684-691
pubmed: 30529387
J Hepatol. 2018 Mar;68(3):526-549
pubmed: 28989095
Liver Cancer. 2019 Jul;8(4):221-238
pubmed: 31602367
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
J Hepatol. 2020 Feb;72(2):342-352
pubmed: 31954496
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Clin Oncol. 2013 Oct 1;31(28):3509-16
pubmed: 23980090
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
J Hepatocell Carcinoma. 2020 Feb 10;7:11-17
pubmed: 32104669
Gut. 2020 Aug;69(8):1492-1501
pubmed: 31801872
J Clin Oncol. 2013 Oct 1;31(28):3501-8
pubmed: 23980077
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Int J Dev Biol. 2015;59(1-3):131-40
pubmed: 26374534
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Clin Colorectal Cancer. 2003 May;3(1):16-8
pubmed: 12777188
J Clin Oncol. 2015 Jun 10;33(17):1974-82
pubmed: 25605845
Oncologist. 2019 Feb;24(Suppl 1):S3-S10
pubmed: 30819826
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
JAMA. 2014 Jul 2;312(1):57-67
pubmed: 25058218
Nat Immunol. 2018 Mar;19(3):222-232
pubmed: 29379119
Clin Cancer Res. 2019 Jun 15;25(12):3486-3494
pubmed: 30833272
Expert Opin Pharmacother. 2017 Oct;18(14):1467-1476
pubmed: 28893090
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Oncol. 2015 Jan 10;33(2):172-9
pubmed: 25488963
Cancers (Basel). 2019 Dec 02;11(12):
pubmed: 31810292
Lancet Oncol. 2008 Jun;9(6):533-42
pubmed: 18495536
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Clin Oncol. 2015 Feb 20;33(6):559-66
pubmed: 25547503
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Expert Opin Investig Drugs. 2011 Mar;20(3):407-413
pubmed: 21314233
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
J Clin Oncol. 2013 Nov 10;31(32):4067-75
pubmed: 24081937
Biochem Biophys Res Commun. 2017 May 20;487(1):1-7
pubmed: 28042031